The company said it can now offer customers "a hosted cell culture development project", which can range from a simple screening experiment to more comprehensive production clone selection, clone stability, media optimization, or process development experiments. According to the company, these services "help clients gain better insight into their bioprocesses and reduce development risk by enabling the design of robust, optimised bioprocesses, faster and more efficiently". The firm said it was responding to a demand for such services, as the biopharmaceutical industry "accelerates its pace to clinical trials in order to identify successful therapeutic candidates sooner". As part of the service offering, BioProcessors will use its SimCell technology, which it says enables the performance of high throughput cell culture experiments for the development and optimisation of biopharma manufacturing processes, allowing full and fractional factorial statistical experiments to be undertaken "at a fraction of the time and cost associated with conventional scale-down technologies". The company's new services offering has been facilitated through the recent expansion of its existing facility in Woburn, Massachusetts, where a second SimCell system was added.
